Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980767 | 0.93 | ELANE (0.47) | ELANELMNAALDH1A1TSHRHTT | |
| SCHEMBL15092965 | 0.85 | ELANE (0.54) | ELANELMNAALDH1A1TSHRTDP1 | |
| SCHEMBL1978866 | 0.85 | LMNA (0.49) | LMNAF2ALDH1A1TSHRHSD17B10 | |
| SCHEMBL1981406 | 0.85 | ALDH1A1 (0.46) | ELANELMNAF2ALDH1A1TSHR | |
| SCHEMBL1981726 | 0.84 | LMNA (0.47) | ELANELMNAF2ALDH1A1TSHR | |
| SCHEMBL1980987 | 0.83 | LMNA (0.46) | ELANELMNAF2ALDH1A1TSHR | |
| SCHEMBL1979142 | 0.82 | LMNA (0.45) | LMNAF2ALDH1A1TSHRHSD17B10 | |
| SCHEMBL1981542 | 0.82 | LMNA (0.45) | LMNAF2ALDH1A1SLC6A3HIF1A | |
| SCHEMBL15092788 | 0.81 | ELANE (0.41) | ELANEALDH1A1TSHRKMT2A | |
| SCHEMBL1982301 | 0.80 | MEN1 (0.51) | LMNAF2ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729312-B2 | Derivatives of novel peroxides, method of preparation thereof and use thereof in human medicine as well as in cosmetics for the treatment or prevention of acne | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-05-20 | — | — | US | claimed |
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-07-11 | — | — | US | claimed |
| US-8729312-B2 | Derivatives of novel peroxides, method of preparation thereof and use thereof in human medicine as well as in cosmetics for the treatment or prevention of acne | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-05-20 | — | — | US | disclosed |
| EP-2509569-B1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RES & DEV (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-07-11 | — | — | US | disclosed |
| EP-2509569-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070171-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GPX4, LPO, GPX1 | ELANE 691/4885LMNA 2502/4885F2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.